when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Ultragenyx Pharmaceutical Inc. ($RARE) · news · pharmadog

← back to Ultragenyx Pharmaceutical Inc.

News mentioning $RARE

837 stories

Jun 12, 26STAT+: Pharmalittle: We’re reading about a discontinued cancer drug, a Novo security breach, and morestat

Jun 11, 26Drinking during pregnancy rose after 2020, new CDC data suggeststat

Jun 11, 26Nonprofit buys experimental cancer drug to maintain patient accessstat

Jun 11, 26Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapybiopharma dive

Jun 11, 26Novartis RNA drug acquired in $12B Avidity deal notches a trial winbiopharma dive

Jun 11, 26J&J looks to widen Imaavy’s use; $300M backs rare disease drug launchbiopharma dive

Jun 10, 26Rare disease biotech Beren adds $300M from new financingsendpoints

Jun 10, 26Sanofi stops immune drug trial in latest research setbackbiopharma dive

Jun 10, 26STAT+: Hope for Kendall Square’s lab marketstat

Jun 10, 26DOJ reaches second settlement on youth gender carestat

Jun 10, 26Sanofi to mull riliprubart’s future after stopping late-stage nerve disease studyendpoints

Jun 9, 26Grace Science says FDA bottleneck jeopardizes rare disease therapyendpoints

Jun 8, 26Health workers at the epicenter of Congo’s Ebola outbreak labor with little pay or reststat

Jun 8, 26STAT+: J&J spends $1 billion to enter KRAS race for cancer treatmentsstat

Jun 6, 26Opinion: How the Amish think about vaccines, health care costs, and much morestat

Jun 5, 26Industry seeks more clarity on commissioner's voucher programendpoints

Jun 5, 26Texas AG investigating energy drinksstat

Jun 5, 26Opinion: How living and practicing medicine abroad complicated my beliefs about universal health care systemsstat

Jun 5, 26Tiny HHS office tasked with protecting research participants’ safety is running on fumesstat

Jun 4, 26HHS confirms Americans with high-risk Ebola exposures will have access to experimental therapystat

Jun 4, 26Acting FDA commissioner pledges to prevent political interference in rare disease meetingendpoints

Jun 4, 26STAT+: RFK Jr.’s second year: Vacancies, not vaccinesstat

Jun 4, 26STAT+: AI titans push Congress for DNA safeguardsstat

Jun 4, 26STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and morestat

Jun 4, 26Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this storystat

Jun 3, 26STAT+: Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeuticsstat

Jun 3, 26STAT+: HaloMD faces lawsuit alleging No Surprises Act middleman used ‘sham letter,’ misleading datastat

Jun 3, 26STAT+: Legend Biotech emerged as a rare market winnerstat

Jun 3, 26Opinion: How the military may be fueling eating disorders in menstat

Jun 3, 26STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patientsstat

← prevpage 23 of 28next →